PROMETHEUS Anser VDZ Build info

Synonyms

• PROMETHEUS ANSER VDZ
• ANSERVDZ
• Vedolizumab
• ENTYVIO Ab
• LAB10852

Short Name

PROMETHEUS ANSER VDZ

Procedure Master Number

LAB10852

Procedure ID

114212

Clinical Info

Serum concentrations of vedolizumab (VDZ) may vary among equally dosed patients which can ultimately affect patient outcomes. Some patients may develop immunogenicity to VDZ by producing antibodies to vedolizumab (ATV) and the presence of persistent anti-vedolizumab antibody has been observed to substantially reduce serum concentrations of vedolizumab. The quantitative measurement of VDZ and ATV levels in serum provides healthcare providers with valuable information to help them gain a better understanding of the factors that may be affecting a patient’s loss of response.
 
The PROMETHEUS Anser VDZ test is a next generation and more sensitive quantitative monitoring assay that allows healthcare providers to measure and monitor serum VDZ and ATV levels at any time during therapy. Incorporating therapeutic drug monitoring may clarify what factors are contributing to a patient’s loss of response and help guide treatment decisions by providing information to help determine an appropriate course of action.

Specimen Type

Container

Gold Top Tube

Collection Instructions

Container/Tube:   Gold top tube
Specimen: 2 mL serum (0.5 ml min)
Transport Temperature:  Room Temperature (stable 7 days) or Refrigerated(stable 9 days)

Transport Instructions

Room Temperature (stable 7 days) or Refrigerated(stable 9 days)

Specimen Stability

Methodology

Electrochemiluminescence Immunoassay (ECLIA)
 
 
Test Includes: 
Serum vedolizumab concentration (VDZ) and Antibodies to vedolizumab (ATV)

Days Performed

Monday - Friday
  TAT = 4 days

Performing Laboratory

Prometheus Therapeutics & Diagnostics

CPT

80280
Ab- If required 82542

PDM

1759072

Results